NASA Awards Launch Service Task Order for Aspera's Galaxy Mission
WASHINGTON, May 14, 2025 /PRNewswire/ -- NASA has selected Rocket Lab USA Inc. of Long Beach, California, to launch the agency's Aspera mission, a SmallSat to study galaxy formation and evolution, providing new insights into how the universe works.
The selection is part of NASA's Venture-Class Acquisition of Dedicated and Rideshare (VADR) launch services contract. This contract allows the agency to make fixed-price indefinite-delivery/indefinite-quantity launch service task order awards during VADR's five-year ordering period, with a maximum total contract value of $300 million.
Through the observation of ultraviolet light, Aspera will examine hot gas in the space between galaxies, called the intergalactic medium. The mission will study the inflow and outflow of gas from galaxies, a process thought to contribute to star formation.
Aspera is part of NASA's Pioneers Program in the Astrophysics Division at NASA Headquarters in Washington, which funds compelling astrophysics science at a lower cost using small hardware and modest payloads. The principal investigator for Aspera is Carlos Vargas at the University of Arizona in Tucson. NASA's Launch Services Program, based at the agency's Kennedy Space Center in Florida, manages the VADR contract.
To learn more about NASA's Aspera mission and the Pioneers Program, visit:
https://go.nasa.gov/42U1Wkn
View original content to download multimedia:https://www.prnewswire.com/news-releases/nasa-awards-launch-service-task-order-for-asperas-galaxy-mission-302455838.html
SOURCE NASA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that exidavnemab was safe and well tolerated. The positive outcome will result in the initiation of two further cohorts, to evaluate a higher dose of exidavnemab in comparison with placebo in patients with Parkinson's disease as well as MSA. "Exidavnemab is BioArctic's second disease modifying treatment for severe brain diseases, building on a similar scientific approach as Leqembi®. Both originate from our antibody platform, selectively targeting aggregated, toxic misfolded proteins. I am pleased that the interim safety review of our phase 2a study EXIST of exidavnemab showed a good safety and tolerability profile as expected, supporting progression into higher doses in both Parkinson's disease and MSA," says Gunilla Osswald, CEO at BioArctic. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile. In addition, a broad range of biomarkers will be evaluated in plasma, cerebrospinal fluid (CSF), and using digital measurements. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab is a monoclonal antibody (mAb) that selectively targets pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregated alpha-synuclein damages nerve cells, and by selectively binding and removing these aggregates, exidavnemab is intended to preserve nerve cell function and slow the disease. There is a large unmet medical need for slowing disease progression in diseases such as Parkinson's disease and MSA. Exidavnemab has recently been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of MSA. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on June 13, 2025, at 08:00 CET. For further information, please contact:Oskar Bosson, VP Communications and Investor RelationsE-mail: mailto: +46 70 410 71 80 About Exidavnemab Exidavnemab is a monoclonal antibody drug candidate that is designed to selectively target and eliminate pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregates of alpha-synuclein participate in neurodegenerative disorders including Parkinson's disease and Multiple System Atrophy (MSA). The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with exidavnemab is ongoing since 2024. EXIST is an important step towards a proof-of-concept study focusing on the efficacy of the drug candidate. Exidavnemab has been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of Multiple System Atrophy (MSA). About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review View original content: SOURCE BioArctic Sign in to access your portfolio
New York Post
2 hours ago
- New York Post
Glamorous social media ‘astronaut' faces NASA backlash after claiming she was picked to head to Space
A Brazilian social media star is facing backlash from NASA after she claimed she was selected as a future astronaut for private missions to the Moon and Mars. NASA jacket-wearing content creator Laysa Peixoto revealed that she was 'going to space' as she stood inside a Manhattan skyscraper with the Empire State Building behind her on June 5. 'I was selected to become a career astronaut, performing on manned spaceflights for private space stations, and future manned missions to the Moon and Mars,' she claimed on Instagram. 'I'm officially an astronaut of the Class of 2025 and will be part of the inaugural Titans Space flight.' 5 Laysa Peixoto poses for a photo wearing a NASA Space Camp flight suit. Instagram/astrolaysa Peixoto claimed she would be joining the private space company's maiden voyage in 2029, commanded by NASA veteran astronaut Bill McArthur. The glamorous tech influencer, who boasts 154,000 followers, says she is Brazil's first female astronaut. 'It is a great joy to represent Brazil as an astronaut in such a decisive era of space exploration, that will change history of mankind forever,' Peixoto added. 'It's an honor to carry the flag of Brazil with me as the first Brazilian woman to cross that border.' Only one Brazilian man, Marcos Pontes, has been to space. Pontes made the historic trip to the International Space Station aboard the Soyuz TMA-8 in March 2006. He is also the only Brazil-born man to complete NASA's astronaut training program. 5 Peixoto wears a NASA jacket during a photo shoot in NYC, she used to announce her acceptance to the Titans Space program. Instagram/astrolaysa Peixoto was selected to be a career astronaut at Titans Space. Only American citizens can be selected for the same title at NASA. An April press release states Titans Space's inaugural flight would include McArthur and three other members – Chris Sembroski, Dr. Mindy Howard and Vaseema Hussain among other talented individuals. There was no mention of Peixoto, but her team claims she is a part of the mission squad and the details are outdated. 'The Titans Space website is out of date, information confirmed by Titans Space representative, who also confirmed Laysa's entry into the company's formation,' Peixoto's agent told Brazilian newspaper O Tempo. 5 Peixoto was selected to be a career astronaut at Titans Space. Instagram/astrolaysa Titans Space offers candidates the opportunity to join its 'Inaugural Astronauts' program for $1 million or an open invitation. The program advertises a five-hour space journey aboard the company's Spaceplane and three hours in zero gravity. Titans Space does not hold a license to conduct manned space flights, the US Sun reported. NASA has denied Peixoto's participation in any upcoming missions with the agency. 'While we generally do not comment on personnel, this individual is not a NASA employee, principal investigator, or astronaut candidate,' NASA said, according to the Daily Mail. 5 The glamorous tech influencer, who has 154,000 followers, says she is Brazil's first female astronaut. Instagram/astrolaysa The government space agency said Peixoto had taken part in a workshop, L'Space Academy, with NASA that wasn't an internship or a job. 'It would be inappropriate to claim NASA affiliation as part of this opportunity,' the agency said. Peixoto returned to Instagram on Thursday to address NASA and Titans Space statements, saying she never claimed to have been selected by the American space agency, having only worn a NASA jacket in the post. 'Maybe many of you didn't get a chance to read what I said when I announced 'I'm going to space,' just the title. The text is available here and in it, I mention WHO selected me, and I mention that it's a PRIVATE space program.' 5 The government space agency said Peixoto had taken part in a workshop, L'Space Academy, with NASA that wasn't an internship or a job. Instagram/astrolaysa 'At no time is there a mention of NASA, or that she would be an astronaut for the agency. The post was never edited,' Peixoto's agent told O Tempo. An 'edited' label is attached to Peixoto's post, but there is no indication of what had been changed. The Post has reached out to NASA and Titans Space for comment. Peixoto's educational background has also been questioned after her, now-deleted, LinkedIn page claimed she worked at NASA when she was 19, was a fellow at the German non-profit Max Planck Society, enrolled in an engineering course at MIT and had a Master's Degree from Columbia University, according to CNN Brazil She studied at Brazil's Federal University of Minas Gerais before transferring to Manhattan College, now Manhattan University, in the Bronx, O Tempo reported.
Digital Trends
5 hours ago
- Digital Trends
NASA's red planet rover shares a cool close-up of Mars mud
NASA's Curiosity rover has been tootling across the martian surface since 2012, its lofty quest to determine if Mars ever had environmental conditions suitable for microbial life. While it's already shared strong evidence that the red planet once had the right conditions for such a scenario, Curiosity continues to learn more about Mars through science expeditions that include drilling for rock samples that it then analyzes in its onboard laboratory. Recommended Videos On Thursday, the hardy rover shared a striking image (top and below) showing its latest drilling site, with the disturbed Mars mudstone appearing so close to the lens that you feel like you can almost reach out and touch it. Take a closer look and marvel at the astonishing detail present in the image, and then consider that it exists not on Earth but in a place currently some 180 million miles from where you're sat now. Meet 'Altadena,' my 43rd drill hole. It's named after a city near where I was built back on Earth. I've got more sampling to do as a I scale Mount Sharp, unraveling its history one rocky layer at a time. — Curiosity Rover (@MarsCuriosity) June 12, 2025 'Meet 'Altadena,' my 43rd drill hole,' Curiosity said in its post. 'It's named after a city near where I was built back on Earth. I've got more sampling to do as a I scale Mount Sharp, unraveling its history one rocky layer at a time.' The mudstone on Mars is a type of sedimentary rock formed from very fine particles of silt and clay that settled in ancient water bodies. It's essentially the remnants of ancient lakebeds, suggesting that Mars held liquid water for an extensive period a long time ago. Curiosity is conducting its work on Mount Sharp, which it's been exploring for much of its time on Mars. The feature is an 18,000-foot-high mountain in the middle of Gale Crater, and whose sedimentary layers, formed over billions of years, hold clues to Mars' watery past and potential habitability. Curiosity's mission was originally supposed to last no more than two years but was extended indefinitely after it successfully met its initial goals. In 2021, NASA landed the even more powerful Perseverance rover on Mars in a mission that complements the Curiosity rover by advancing the search for signs of ancient microbial life on the planet.
